Literature DB >> 18346684

Acute variceal bleeding: pharmacological treatment and primary/secondary prophylaxis.

A Dell'Era1, R de Franchis, F Iannuzzi.   

Abstract

Variceal bleeding is one of the most severe complications of portal hypertension related to liver cirrhosis. Primary prophylaxis is considered mandatory in patients with cirrhosis and high-risk oesophageal varices, and once varices have bled, every effort should be made to arrest the haemorrhage and prevent further bleeding episodes. In acute variceal bleeding, vasoactive drugs that lower portal pressure should be started even before endoscopy, and should be maintained for up to 5 days. The choice of vasoactive drug should be made according to local resources. Terlipressin, somatostatin and octreotide can be used; vasopressin plus transdermal nitroglycerin may be used if no other drug is available. In variceal bleeding, antibiotic therapy is also mandatory. In primary and secondary prophylaxis, beta-blockers are the mainstay of therapy. In secondary prophylaxis (but not in primary prophylaxis) these drugs can be combined with organic nitrates.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18346684     DOI: 10.1016/j.bpg.2007.11.001

Source DB:  PubMed          Journal:  Best Pract Res Clin Gastroenterol        ISSN: 1521-6918            Impact factor:   3.043


  7 in total

1.  Acute esophageal variceal bleeding: Current strategies and new perspectives.

Authors:  Salvador Augustin; Antonio González; Joan Genescà
Journal:  World J Hepatol       Date:  2010-07-27

2.  Endoscopic hemostasis techniques for upper gastrointestinal hemorrhage: A review.

Authors:  Hajime Anjiki; Terumi Kamisawa; Masaki Sanaka; Taro Ishii; Yasushi Kuyama
Journal:  World J Gastrointest Endosc       Date:  2010-02-16

3.  Short-term vasoactive agent treatment driven by physicians' preference in acute esophageal variceal bleeding in a tertiary center.

Authors:  Yoen Young Chuah; Ping-I Hsu; Wei-Lun Tsai; Hsien-Chung Yu; Feng-Woei Tsay; Wen-Chi Chen; Kung Hung Lin; Yeong Yeh Lee; Huay-Min Wang
Journal:  PeerJ       Date:  2019-11-06       Impact factor: 2.984

4.  Selective gene expression profiling contributes to a better understanding of the molecular pathways underlying the histological changes observed after RHMVL.

Authors:  Janine Arlt; Sebastian Vlaic; Ronny Feuer; Maria Thomas; Utz Settmacher; Uta Dahmen; Olaf Dirsch
Journal:  BMC Med Genomics       Date:  2022-10-07       Impact factor: 3.622

5.  No mortality difference following treatment with terlipressin or somatostatin in cirrhotic patients with gastric variceal hemorrhage.

Authors:  Tsung-Hsing Hung; Chen-Chi Tsai; Guo-Chih TsenK; Yu-Hsi Hsieh; Chih-Wei Tseng
Journal:  Saudi J Gastroenterol       Date:  2016 May-Jun       Impact factor: 2.485

6.  No difference in mortality between terlipressin and somatostatin treatments in cirrhotic patients with esophageal variceal bleeding and renal functional impairment.

Authors:  Tsung-Hsing Hung; Chen-Chi Tsai; Chih-Wei Tseng; Kuo-Chih Tseng; Yu-Hsi Hsieh; Chih-Chun Tsai
Journal:  Eur J Gastroenterol Hepatol       Date:  2016-11       Impact factor: 2.566

Review 7.  Vasopressin and Its Analogues: From Natural Hormones to Multitasking Peptides.

Authors:  Mladena Glavaš; Agata Gitlin-Domagalska; Dawid Dębowski; Natalia Ptaszyńska; Anna Łęgowska; Krzysztof Rolka
Journal:  Int J Mol Sci       Date:  2022-03-12       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.